CVM
CEL-SCI Corporation5.90
-0.10-1.67%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
47.16MP/E (TTM)
-Basic EPS (TTM)
-9.13Dividend Yield
0%Recent Filings
10-Q
Q1 FY2026 results
CEL-SCI trimmed its Q1 FY2026 operating loss to $5.4M from $6.9M y/y, driven by R&D expenses dropping to $3.7M from $4.4M and G&A to $1.7M from $2.5M, while net loss narrowed to $5.5M or $(0.68) per share on 8.0M weighted shares—less dilutive than last year's 2.2M shares yielding $(3.25). Cash burned $4.7M q/q to $6.3M amid $4.0M operating outflows, no capex, and $0.7M finance lease payments on $7.4M obligation (8.5% rate, 2.8-year term). Lease costs held steady. Equity comp fueled the gap between operating and net loss. Cash is running low.
10-K
FY2025 results
CEL-SCI Corporation, a late-stage biotech, reported no revenue for FY2025 ended September 30, 2025, as its investigational immunotherapy Multikine awaits regulatory approval following positive Phase 3 survival data in low PD-L1 head and neck cancer patients. Lacking financial statements or quarterly breakdowns in the 10-K, topline and profitability metrics remain undisclosed. No Q4 momentum indicators or segment trends provided. Liquidity details and capital allocation actions not specified. No annual guidance disclosed. Clinical trial delays threaten quarterly progress.
8-K
Revised shareholder rights plan
8-K
CEL-SCI extends rights agreement
CEL-SCI Corporation amended its Shareholder Rights Agreement on October 30, 2025, extending its expiration from the original date to October 30, 2030. This poison pill update bolsters defenses against hostile takeovers, preserving board control amid biotech volatility. The board acted decisively. No financial impacts or further terms were disclosed.
8-K
CEL-SCI closes $10M offering
CEL-SCI closed a $10 million public offering on August 29, 2025, selling 1,111,200 shares at $9.00 each through ThinkEquity. Gross proceeds will fund Multikine development, corporate purposes, and working capital, bolstering the biotech's clinical pipeline. Yet lock-up restrictions bind insiders for 45 days. Forward-looking plans hinge on regulatory risks.
CELC
Celcuity Inc.
100.39-1.79
CELU
Celularity Inc.
1.35-0.05
CLCS
Cell Source, Inc.
0.45+0.08
CLDI
Calidi Biotherapeutics, Inc.
1.30-0.03
CLLS
Cellectis S.A.
4.06-0.73
CLRB
Cellectar Biosciences, Inc.
3.18-0.02
CUE
Cue Biopharma, Inc.
0.41-0.05
PDSB
PDS Biotechnology Corporation
0.90-0.02
REPL
Replimune Group, Inc.
9.61-0.34
VCEL
Vericel Corporation
35.50-0.99